Despite contemporary typing procedures for bone marrow transplantation (BMT), graft-versus-host disease (GVHD) continues to be a major complication of transplants performed between MHC-matched donors and recipients. Although GVHD can be alleviated by T cell depletion, this procedure increases the risk of graft failure and leukemic relapse and therefore is not a solution to the GVHD problem. The high degree of variation in the intensity of GVHD observed in different patients suggests that multiple non-MHC genetic factors influence GVHD severity. We hypothesize that, in addition to minor histocompatibility antigen disparities, polymorphisms in genes encoding immunologic effector molecules may be important factors influencing GVHD development. This study aims to explore this hypothesis by identifying non-MHC genes that influence the outcome of BMT in a murine model. In this model, B10.D2 donor leukocytes cause acute GVHD in (C57BL/6 × DBA/2)F1 (B6D2F1) recipients, whereas DBA/2 donor leukocytes do not. To date, a locus on chromosome 1 has been identified as influencing the severity of GVHD in this model. Our current study shows that a locus on chromosome 2 acts independently of the chromosome 1 locus to also influence GVHD severity in this model. The region of chromosome 2 implicated in our study contains genes encoding ␤ 2 -microglobulin, the minor histocompatibility antigen H-3 and the pro-inflammatory cytokine IL-1.
antigens have been studied. While minor histocompatibility antigens are undoubtedly instrumental in the development of GVHD, [3] [4] [5] a second factor that may also influence the severity of GVHD is the presence of polymorphisms in immunologically relevant genes.
To date, polymorphisms in numerous genes encoding molecules that play various roles in the immune system have been found in humans. These include polymorphisms in the genes encoding IL-10, 6 IL-4, 7 IL-1␣, 8, 9 IL-1␤, 10 the IL-1 receptor antagonist, 10, 11 TNF-␣, 12 and Fc receptors. 13 Several of these immunological polymorphisms have been reported to significantly influence immune function or affect the development or severity of one or more immunological disorders. 10, [13] [14] [15] [16] For example, a polymorphism in the IL-10 promoter has been reported to affect the severity of systemic lupus erythematosus. 15 Polymorphisms in genes encoding immunologic effector molecules have also been implicated in solid tissue rejection. Recently, a specific combination of polymorphic alleles of the genes encoding TNF-␣ and IL-10 found in human heart transplant patients has been reported to influence susceptibility to early rejection of heart transplants. 17, 18 There is no reason why polymorphisms in immunological effector molecules might not also significantly influence the course of GVHD occurring after BMT.
In this study we aimed to investigate the genetic factors that can affect the severity of GVHD by identifying genetic loci that influence GVHD development in an MHC-mismatched murine model. In this model, lymphoid cells from B10.D2 donors cause acute GVHD in B6D2F1 recipients whereas lymphoid cells from DBA/2 donors do not. Rather, recipients of DBA/2 lymphoid cells develop chronic GVHD. This model and other closely related murine models have been used widely in studies of GVHD. [19] [20] [21] [22] We previously identified a locus on chromosome 1 that exerts a major influence on the development of acute GVHD in this model. 23, 24 Candidate genes on chromosome 1 include the gene encoding the superantigen Mtv7 and the gene encoding the cell surface molecule CD48. Mtv7 is an endogenous superantigen that can influence negative selection of T cells. B10.D2 mice lack Mtv7 whereas DBA/2 mice express this superantigen. Recognition of the Mtv7 superantigen in B6D2F1 recipients by B10.D2 donor cells could hypothetically influence the course of the subsequent GVHD. Evidence has recently been presented that Mtv antigens can indeed influence GVHD. 25, 26 CD48 is the murine ligand of CD2, which has recently been implicated in Th1/Th2 switching. 27 A polymorphism in the CD48 gene could hypothetically influence Th1/Th2 switching, thereby influencing the course of GVHD.
In the present study, we show that a locus on chromosome 2, independently of the chromosome 1 locus, also exerts a significant influence on the severity of acute GVHD in this model.
Materials and methods

Mice
Recipient (C56BL/6 × DBA/2)F1 mice (B6D2F1) and donor B10.D2/nSnJ (B10.D2) and DBA/2J (DBA/2) control mice were obtained from The Jackson Laboratory (Bar Harbor, ME, USA) or Harlan Sprague Dawley (Indianapolis, IN, USA). (B10.D2 × DBA/2) × B10.D2 backcross mice (B10.D2 BX) and (B10.D2 × DBA/2) × DBA/2 backcross mice (DBA/2 BX) were bred in the animal facility of the Department of Biology at Indiana University-Purdue University at Indianapolis.
The MHC haplotypes of the strains used are as follows:
. Throughout the work described, all donor mice were H-2 d and, therefore, in all cases studied GVHD was driven by recognition of the foreign H-2 b alleles expressed in the recipient B6D2F1 mice.
Generation and assessment of GVHD
Cells were isolated from the spleen and lymph nodes (axillary and brachial) of 5-10 week old donor backcross or control mice. Red blood cells were lysed and the remaining leukocytes were washed twice in culture medium. Isolated lymphocytes were finally diluted in 0.9% freshly autoclaved saline to a concentration of approximately 3.0 × 10 8 cells/ml. 0.5 ml of this cell suspension was injected intravenously into the tail vein of 5-10 week old B6D2F1 recipients. Donors were either male or female. In order to avoid variation associated with recognition of the H-Y antigen by donor cells only female recipient mice were used (as H-Y is not expressed by female mice).
In the model studied, weight loss and/or death within 30 days post-transfer are the primary markers of acute GVHD, although they are often accompanied by inactivity and a hunched appearance of the afflicted animal. Hair loss is not associated with the acute GVHD occurring in this model. B6D2F1 recipients of DBA/2 lymphoid cells do not show these characteristics of acute GVHD, but rather develop a chronic GVHD syndrome characterized by high levels of autoantibodies and development of proteinuria and renal disease. 20, 21 In our laboratory, approximately 60-70% of B6D2F1 recipients of DBA/2 lymphoid cells develop chronic GVHD within 6 months of cell transfer.
Acute GVHD-associated weight loss was monitored by weighing mice on an approximately daily basis for the first 30 days post-transfer. Weight loss is expressed in the Results as the maximum percentage weight loss occurring during this time, ie the maximum percentage difference attained between any weight during this time and any lesser weight subsequently attained within the 30 day time period.
For those mice that died during the first 30 days post-transfer, maximum percent weight loss was calculated as described above using the weights obtained up to the day of death. Death occurred without significant weight loss in Ͻ10% of mice that died and, therefore, had little impact on the results. 28 The following cycle was repeated 39 times: 95°C for 1 min, the appropriate annealing temperature for 1 min, and 72°C for 1 min plus 1 s/cycle. A final cycle with an extension phase of 10 min at 72°C followed the 39th cycle. The resulting product was run on a 4% Metaphor agarose gel (FMC Bioproducts, ME, USA) at 7.8 V/cm.
Statistical analyses
Mean maximum percent weight loss comparisons were performed using Mann-Whitney analysis.
Interval mapping was performed using the Map Manager QT linkage analysis software 29 (version b21). The significance of LOD scores was determined using the permutation test method of Churchill and Doerge, 30 as implemented in the Map Manager QT linkage analysis software (using 1000 permutations to estimate significance levels).
Results
Weight loss as an indicator of acute GVHD
Acute GVHD in the B10.D2 → B6D2F1 model is characterized by significant weight loss or death within 30 days post-transfer. 24, 31 Because this is the major pathological outcome of acute GVHD, we aimed to identify genetic loci influencing this aspect of GVHD. To observe weight loss patterns during the first 30 days post-transfer, 1.2-1.5 × 10 8 lymphoid cells were isolated from B10.D2, DBA/2 or B6D2F1 mice and injected into B6D2F1 recipients. Representative weight curves of the recipients are shown in In order to reduce the course of weight fluctuation within the 30 day period to a single value, we calculated the maximum percent weight loss during the first 30 days posttransfer for each mouse. This value corresponds to the maximum percent difference between any weight during that time and any lesser weight subsequently attained within the 30 day period. Analysis of the maximum percent weight loss during the first 30 days post-transfer of a large number of B6D2F1 recipient mice that received 1.2-1.5 × 10 8 cells from B10.D2 donors, DBA/2 donors, or B6D2F1 mice, or that received saline injections, yielded the results shown in Figure 2 .
The maximum percent weight losses shown in Figure 2 demonstrate that significant weight loss is associated only with the development of acute GVHD in B6D2F1 recipients of B10.D2 cells and not with the development of chronic GVHD in recipients of DBA/2 cells. Of those mice receiving B10.D2 lymphoid cells 38% (22/57) died during the first 30 days post-transfer. In 95% (21/22) of these cases mortality was accompanied by significant weight loss. Significant weight loss was rarely observed in recipients of DBA/2 or B6D2F1 cells or in recipients of saline injections, indicating that few 'false positives' occur. A cut-off above which recipients were considered positive for acute GVHD was determined using the mean maximum percent weight loss of recipients of DBA/2 cells, which was 6.73%. The 99.9% upper confidence limit for the DBA/2 cell recipients was 13.1% (mean Ϯ 2.6 standard deviations). Using this as a limit, the false positive rate in all of the B6D2F1 recipients of DBA/2 cells, B6D2F1 cells, and saline was 1.5% (1/66). Some variation in weight loss is observed in the recipients of cells from B10.D2 donors. This is similar to the variation in GVHD severity routinely observed in many murine GVHD models and may be due to random environmental or experimental variation. For the purposes of initial mapping studies, only those backcross donors that caused greater than 13.1% weight loss in B6D2F1 recipients were used, as there was little chance that there could be 'false positives.'
Analysis of backcross mice
In order to map loci influencing the development of acute GVHD, (B10.D2 × DBA/2) × B10.D2 backcross mice (B10.D2 BX) and (B10.D2 × DBA/2) X DBA/2 backcross mice (DBA/2 BX) were used as donors. B10.D2 BX mice are homozygous for B10.D2 alleles at approximately 50% of their loci and heterozygous at all remaining loci, whereas DBA/2 BX mice are homozygous for DBA/2 alleles at approximately 50% of their loci and heterozygous at the remaining loci.
Previous work reported by Van Elven et al 31 suggested that the ability of donor mice to induce acute GVHD is a recessive trait. If this is indeed the case, we would expect to see a significant proportion of the B10.D2 BX mice able to induce acute GVHD (those homozygous for B10.D2 alleles at the locus (loci) involved) while few if any DBA/2 BX mice would be able to induce acute GVHD (since none could be homozygous for recessive B10.D2 alleles).
1.2 -1.5 × 10 8 backcross donor cells were used to induce GVHD in B6D2F1 recipients. Weights of the recipient mice were monitored during the first 30 days post-transfer and maximum percent weight losses determined (Figure 3 ). These recipient mice demonstrated varied responses to the 29 Significance levels were calculated using the permutation test method of Churchill and Doerge, 30 as implemented in the Map Manager QT linkage analysis software (using 1000 permutations). This method indicated that, for the data set used, LOD scores greater than 6.9 are significant at the P = 0.05 level (indicated as 'Significant'), while LOD scores greater than 13.7 are significant at the P = 0.001 level (indicated as 'Highly significant'). The approximate positions of candidate loci relative to the linkage markers used were determined using the Mouse Genome Database. 28 Note: all mice in this analysis were heterozygous at D1Mit57. These data support the existence of one or more loci at which recessive B10.D2 alleles influence the development of acute GVHD (since a significantly greater proportion of B10.D2 BX mice than DBA/2 BX mice caused significant weight loss in recipient mice).
Linkage analysis
Previous studies conducted in our laboratory indicated that a locus on chromosome 1 linked to the marker D1Mit57 influences the severity of acute GVHD in this model. 23, 24 Analysis of the mean maximum percent weight losses in B6D2F1 recipients of B10.D2 BX cells revealed significantly different maximum percent weight losses between recipients of cells from B10.D2 BX mice that were homozygous at the marker D1Mit57 and recipients of cells from B10.D2 BX donors that were heterozygous at D1Mit57 a n = number of donor mice with the genotype given. b Mean ± standard deviation. There was no significant difference between the initial weights of mice in each group (initial weight of B/B group = 18.5 ± 1.7 g (median = 18.4 g); initial weight of B/D group = 18.6 ± 1.4 g (median = 18.5 g)). c Probability was determined by Mann-Whitney analysis. Analysis by one-tailed Student's t-test yielded a probability of 0.006 (P = 0.0086 by Mann-Whitney analysis; Table 1 ). These results agree with the previous findings that a gene on chromosome 1 influences the development and severity of acute GVHD. However, 24/55 (44%) B6D2F1 recipients that were positive for acute GVHD received cells from donors that were heterozygous at D1Mit57. Since 'false positives' do not occur at a significant rate, this implies that loci other than the chromosome 1 locus influence the outcome of GVHD. Homozygosity at one or more such loci could, perhaps, exert a strong enough influence in donor mice that were heterozygous at D1Mit57 to cause acute GVHD. In order to identify other loci that may play a role in the development of acute GVHD, further PCR-based linkage analysis was carried out. Further analyses of the genomes of donor mice that were heterozygous at D1Mit57 and caused significant weight loss were performed. These 24 mice were screened for 61 markers spread throughout the genome in an initial search for markers at which a majority of the mice that caused acute GVHD-associated weight loss were homozygous for B10.D2 alleles. This screen covered approximately 90% of the genome. Two linkage markers, D2Mit62 and D10Mit51, gave 2 values of greater than 3.84 (ie P Ͻ 0.05) when tested against the null hypothesis that homozygotes and heterozygotes were present in a 1:1 ratio. All 85 B10.D2 BX mice that were heterozygous at D1Mit57 were then typed for D2Mit62 and D10Mit51. D10Mit51 was found to be not significantly associated with the weight loss phenotype whereas significant linkage was found to the marker D2Mit62. Table 2 shows the mean maximum percent weight losses a n = number of donor mice with the genotype given. b Mean ± standard deviation. There was a slight difference between the initial weights of mice in each group (initial weight of B/B group = 18.3 ± 1.2 g (median = 18.2 g)). initial weight of B/D group = 18.9 ± 1.5 g (median = 18.55 g)). This difference was of borderline signficance (P Ͼ 0.05 by MannWhitney analysis; P = 0.05 by two-tailed Student's t-test). The donor mice were not genotyped prior to transfer of their cells to recipient mice and so the difference in initial weights between groups can only be attributed to random variation. At any rate, a difference in mean initial weights of 0.6 g would contribute little to the overall percent weight loss calculated and could not account for the large difference in maximum percent weight loss observed between the two groups. c Probability was determined by Mann-Whitney analysis. Analysis by one-tailed Student's t-test yielded a probability of 0.0006. d The proportion of mice that were heterozygous at this locus and caused significant weight loss is significantly different than the proportion of mice that were homozygous at this locus and caused significant weight loss ( 2 = 12.144, P Ͻ 0.001).
in B6D2F1 recipients of B10.D2 BX cells with regards to heterozygosity or homozygosity at the marker D2Mit62. B10.D2 BX donors that were homozygous at D2Mit62 caused a mean percent weight loss of 14.8% while B10.D2 BX donors that were heterozygous at D2Mit62 caused a mean maximum percent weight loss of 9.2%. Analysis by the Mann-Whitney test demonstrated that these mean weight loss values are significantly different from one another (P = 0.0007). This evidence implies that a gene on chromosome 2 influences the severity of acute GVHD. An interval mapping analysis of chromosome 2 was also carried out. The results suggest significant linkage in the area surrounding the marker D2Mit62 (Figure 4 ). This area contains several relevant candidate genes which are shown at their respective locations. Table 3 summarizes the effect of genotype at the D1Mit57 and D2Mit62 linkage marker loci on the severity of acute GVHD. B10.D2 BX donors that were homozygous at only D1Mit57 did not cause a significantly different mean percent weight loss in B6D2F1 recipients than those B10.D2 BX donors that were homozygous only at the marker D2Mit62. Donors that were homozygous at either D1Mit57 or D2Mit62 did, however, cause a significantly greater mean maximum percent weight loss than those donors that were heterozygous at both loci. Homozygosity at both loci does not cause a significant increase in the severity or incidence of acute GVHD over those donors that were homozygous at only one locus. This suggests that loci on chromosome 1 and chromosome 2 act independently of one another in influencing GVHD severity. Table 3 Relationship between genotype at the linkage markers D1Mit57 and D2Mit62 and acute-GVHD incidence and severity Mean ± standard deviation. There were slight differences between the initial weights of mice in each group (initial weight of 'both B/B' group = 18.5 ± 1.9 g (median = 18.4 g); initial weight of '1 B/B and 2 B/D' group = 18.5 ± 1.5 g (median = 18.2 g); initial '1 B/D and 2 B/B' group = 18.3 ± 1.2 g (median = 18.2 g); initial weight of 'neither B/B' group = 18.9 ± 1.5 g (median = 18.55 g)). The only difference approaching significance was that between the last two groups -see the footnote to Table 2 . 
Discussion
The genetic analysis presented above suggests that a gene on chromosome 2 of the mouse influences the severity of acute GVHD in the B10.D2 → B6D2F1 model. Potential candidate genes in the area of chromosome 2 implicated in this study are the genes for ␤ 2 -microglobulin, the minor histocompatibility antigen loci H3a and H3b, and the gene encoding the inflammatory cytokine IL-1. It is possible that polymorphisms in these genes between different donors may influence the severity of acute GVHD. ␤ 2 -microglobulin is a gene that is known to be polymorphic in the mouse [32] [33] [34] and polymorphism in ␤ 2 -microglobulin has been shown to influence the range of peptides presented by class I MHC in mice. 35 It is conceivable, therefore, that polymorphism in ␤ 2 -microglobulin could account for our results. However, a recent study demonstrated that skin grafts are routinely accepted between strains of mice with different allelic forms of ␤ 2 -microglobulin. 36 This suggests that polymorphism at this locus is not associated with significant histoincompatibility and, therefore, is unlikely to significantly influence the severity of GVHD.
Another potential candidate gene is the H-3 minor histocompatibility locus, which actually consists of two loci, H3a and H3b. 37 While a minor histocompatibility locus such as H-3 could certainly influence GVHD, it is difficult to see why the presence or absence of a single minor histocompatibility antigen would significantly modify the severity of GVHD caused by an entire MHC-mismatch (as is the case in the model we have studied). Furthermore, Blazar et al 38 demonstrated that disparity at the H-3 locus is unable to elicit GVHD in a murine model, indicating that this is neither a particularly strong histocompatibility antigen nor particularly able to induce GVHD.
The final candidate locus on chromosome 2 is the IL-1 locus. Although the IL-1 gene is not known to be functionally polymorphic in mice, the human genome is polymorphic not only at IL-1␣, 8, 9 but also at IL-1␤ 10 and at the IL-1 receptor antagonist locus. 10, 11 This degree of polymorphism suggests some functional importance of IL-1 polymorphism. It might, therefore, be reasonably expected that similar polymorphisms may also exist in the mouse genome. Several studies have implicated the human IL-1 polymorphism as playing a modifying role in various immunological diseases, including myasthenia gravis, 39 type I diabetes mellitus 16 and inflammatory bowel disease. 10 IL-1 is also known to be an important mediator of acute GVHD [40] [41] [42] [43] and it is easy to imagine how a polymorphism which influences levels of IL-1 expression could exert a significant modifying effect on the course of GVHD. We therefore believe that the most likely candidate gene on chromosome 2 at this time is the IL-1 locus.
In order to map a gene it is necessary to work with a very defined phenotype. For this reason, we focused in this study solely on acute GVHD-associated weight loss. This allowed us to map the chromosome 2 locus. In order to investigate more broadly the effects of this locus on GVHD, we are currently breeding a congenic strain that has B10.D2 alleles at all parts of the genome except for the segment on chromosome 2 implicated in this study, at which the congenic strain will bear DBA/2 alleles. This strain will allow us to examine specifically how the chromosome 2 locus influences the development of other aspects of acute GVHD. Further genomic screening of B10.D2 BX donor mice is also underway to identify any other loci involved.
Irrespective of which gene the locus on chromosome 2 corresponds to, the unquestionable finding of our study is that discrete, non-MHC loci can significantly influence the course of GVHD occurring in an MHC-mismatched setting. Even in the presence of an entire MHC mismatch, acute GVHD can be either mild or severe, depending to a significant extent on the genotype of the donor at specific non-MHC loci. In the light of this observation, and in light of considerable recent data suggesting that the course of various immunological disorders in humans is significantly influenced by polymorphisms in genes encoding key immunological mediators, 10, 15, 16, 39 it is perhaps time for us to pay more attention to the impact of such polymorphism on GVHD and to broaden our scope beyond consideration of only major and minor histocompatibility antigens as potential determinants of GVHD risk.
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